Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

Prior treatment

• Recent use of systemic antibiotics, steroids, or immunomodulators (within 4 weeks)
• Use of topical or systemic treatment during previous weeks liable to interfere with assessment
• Subject having undergone surgery under general anaesthesia within the previous month
• Excessive exposure to sunlight or UV-rays within the previous month

Other illness

• Recent (within 4 weeks) or current history of using atopic dermatitis biological drugs, such as dupilumab, lebrikizumab, nemolizumab, and tralokinumab
• Active skin infections unrelated to atopic dermatitis
• Severe dermatologic conditions requiring immediate medical intervention

Other

• Pregnant or nursing woman or woman planning to get pregnant during the study
• Subject having scars, tattoos on the forearms that would interfere with assessments
• Subject enrolled in another clinical trial during the study period and/or during the past 30 days

• Previously diagnosed Atopic Dermatitis with active, visible flare-ups at time of screening
• Present dry/itchy skin patches on forearm, back of the hand, or posterior lower leg suitable for treatment assessment
• Evidence of inflammatory disease (documented diagnosis and current active symptoms)
• Stable skincare routine for 4 weeks prior to screening
• Subject willing to avoid conflicting topical treatments during study period
• Subject being used to applying topical treatments for atopic dermatitis
  • General:
• Healthy subject apart from atopic dermatitis
• Subject having given free informed, written consent
• Subject willing to adhere to protocol and study procedures